Gabapentin Capsule
Product Images NDC 76420-790

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76420-790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules, Usp 100 mg-label (Gabapentin 100mg Label)

Label sheet displaying multiple packaging labels for Gabapentin Capsules USP 100 mg from Enovachem Pharmaceuticals. Labels show various package sizes including quantities of 30, 60, 90, 100, and 500 capsules. They include information such as the NDC numbers, manufacturer SciGen Pharmaceuticals, Inc., opaque white capsules, storage instructions, and Federal law dispensing warnings.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The graph shows a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain scores, ranging from 0 to 10, and the x-axis represents weeks from baseline to week 8. Gabapentin shows a decline in pain scores over time, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over 7 weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks from baseline through a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Both gabapentin doses show a decrease in mean pain score over time compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at varying doses across two studies. The y-axis represents responder proportion percentages, showing higher response rates for Gabapentin doses of 1800 mg, 2400 mg, and 3600 mg compared to placebo, with statistical significance indicated.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula depicting the calculation for creatinine clearance (CLCr), involving age, weight, serum creatinine levels, and a factor for female patients. The formula uses weight in kilograms and serum creatinine in mg/dL values.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram of the active ingredient gabapentin. The illustration shows a cyclohexane ring bonded to an amino methyl and carboxymethyl group.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing difference percentages for three separate studies (labeled Study a, Study b, Study c) across four daily gabapentin doses (600 mg, 900 mg, 1200 mg, 1800 mg). Percentage difference is plotted on the vertical axis and daily dose in milligrams on the horizontal axis, with distinct symbols for each study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.